LDLR and Dravet syndrome: Nevertheless, further studies of pcsk9 and ldlr protein levels in the liver, as well as evaluation of PC5/6 levels during OEA-DS therapy, are required to definitively confirm the presence of this “dual mechanism” in OEA-DS.